The Ministry of Health, Labor, and Welfare (MHLW) in Japan has granted Orphan Drug Designation (ODD) to Lundbeck's investigational drug, amlenetug, a potential new treatment option targeting Multiple ...

Join Dr. Raymond A. Huml, Vice President of Rare Strategy, Sciensus; Andrew Cummins, Vice President of Business Development, Sciensus; and Kirsty Hoyle, CEO, Metabolic Support UK, for the live webinar ...

India aims for Rs 17,000 crore investment in pharma R&D by FY28 through PRIP scheme, focusing on innovation and growth.

UK-based public health agency, Knowledge?Action?Change (K?A?C), is launching a free online course called Understanding ...

Sigrid Therapeutics (Sigrid) is excited to announce that it has secured U.S. market access for its proprietary SiPore� technology, following the success of the SHINE study, the largest of its kind in ...

In today’s evolving pharmaceutical environment, the fill‐finish segment stands out as a critical linchpin connecting drug ...

The TSXV serves as a vital platform for early-stage, high-growth companies, providing access to capital and a strong investor network. In 2024, 80% of the TSXV Venture 50™ companies operated ...

Montpellier, France Monday, March 10, 2025, 15:00 Hrs [IST] ...

Positive results from the pivotal ADEPT phase 2/3 study evaluating the investigational use of Dupixent (dupilumab) in adults with moderate-to-severe bullous pemphigoid (BP) were shared in a ...

RBC Capital analyst Brian Abrahams initiated coverage of Aardvark Therapeutics (AARD) with an Outperform rating and $21 price target Aardvark ...